Thedevelopment of a once-weekly basal insulin with a longer, flatter exposure profile, coupledwith controlled tissue distribution properties and attenuated potency at the insulin receptor(IR) could reduce variability by controlling fluctuations in glucose levels during the week,while maintaining an acceptable and manageable hypoglycemia profile. Here, INS is linked to Hypoglycemia.